DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Information source: Kessler Foundation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Aphasia; Stroke

Intervention: Levetiracetam (Drug); Levetiracetam (Drug)

Phase: Phase 1

Status: Active, not recruiting

Sponsored by: Kessler Foundation

Official(s) and/or principal investigator(s):
A.M. Barrett, MD, Principal Investigator, Affiliation: Kessler Foundation

Summary

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Clinical Details

Official title: Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Speech and language assessment

Secondary outcome: Memory assessment

Detailed description: In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Stroke

- Aphasia

- Can give consent

Exclusion Criteria:

- Renal failure

- Pregnancy

- Other neurological condition

Locations and Contacts

Kessler Foundation, West Orange, New Jersey 07052, United States
Additional Information

Starting date: September 2005
Last updated: March 31, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017